| Literature DB >> 32287324 |
Nizam Ahmad1, El Hassane Anouar2, Amalina Mohd Tajuddin1,3, Kalavathy Ramasamy4,5, Bohari M Yamin6, Hadariah Bahron1.
Abstract
This paper reports the synthesis, characterization, anticancer screening and quantum chemical calculation of a tetradentate Schiff base 2,2'-((1E,1'E)-((2,2-dimethylpropane-1,3-diyl)bis- (azanylylidene))bis(methanylylidene))bis(4-fluorophenol) (L2F) and its Pd (II) complex (PdL2F). The compounds were characterized via UV-Visible, NMR, IR spectroscopy and single crystal x-ray diffraction. Density Functional Theory (DFT) and time-dependent DFT calculations in gas and solvent phases were carried out using B3LYP, B3P86, CAM-B3LYP and PBE0 hybrid functionals combined with LanL2DZ basis set. Complexation of L2F to form PdL2F was observed to cause a bathochromic shift of the maximum absorption bands of n-π* from 327 to 410 nm; an upfield shift for δ (HC = N) from 8.30 to 7.96 ppm and a decreased wavenumber for ν(C = N) from 1637 to 1616 cm-1. Overall, the UV-Vis, NMR and IR spectral data are relatively well reproduced through DFT and TD-DFT methods. L2F and PdL2F showed IC50 of 90.00 and 4.10 μg/mL, respectively, against human colorectal carcinoma (HCT116) cell lines, signifying increased anticancer activity upon complexation with Pd (II).Entities:
Mesh:
Substances:
Year: 2020 PMID: 32287324 PMCID: PMC7156068 DOI: 10.1371/journal.pone.0231147
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Synthesis of L2F.
Fig 2Synthesis of PdL2F.
λMAX (nm), EMAX (eV), f of π→π* transitions of L2F and PdL2F calculated using B3LYP, PBE0, CAM-B3LYP and PBE0 hybrid functional in gas, IEF-PCM and SS-PCM.
| Gas | IEF-PCM | SS-PCM | Experimental | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| λMAX | EMAX | λMAX | EMAX | λMAX | EMAX | λMAX | EMAX | ||||
| L2F | 259 | 4.79 | 0.29 | 257 | 4.82 | 0.48 | 260 | 4.77 | 0.67 | 257 | 4.82 |
| PdL2F | 259 | 4.78 | 0.20 | 258 | 4.80 | 0.39 | 261 | 4.75 | 0.60 | 255 | 4.86 |
| L2F | 258 | 4.81 | 0.28 | 256 | 4.84 | 0.47 | 259 | 4.79 | 0.67 | 257 | 4.82 |
| PdL2F | 256 | 4.84 | 0.16 | 254 | 4.87 | 0.32 | 257 | 4.83 | 0.48 | 255 | 4.86 |
| L2F | 235 | 5.28 | 0.38 | 234 | 5.29 | 0.46 | 237 | 5.23 | 0.62 | 257 | 4.82 |
| PdL2F | 223 | 5.57 | 0.68 | 232 | 5.35 | 0.65 | 236 | 5.25 | 0.93 | 255 | 4.86 |
| L2F | 247 | 5.01 | 0.47 | 247 | 5.02 | 0.58 | 250 | 4.95 | 0.77 | 257 | 4.82 |
| PdL2F | 247 | 5.02 | 0.25 | 245 | 5.05 | 0.48 | 248 | 4.99 | 0.68 | 255 | 4.86 |
λMAX (nm), EMAX (eV), f of electronic transitions of L2F (n→π*) and its complexes and PdL2F (n→d) calculated using B3LYP, PBE0, CAM-B3LYP and PBE0 hybrid functional in gas, IEF-PCM and SS-PCM.
| Gas | IEF-PCM | SS-PCM | Experimental | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| λMAX | EMAX | f | λMAX | EMAX | f | λMAX | EMAX | λMAX | EMAX | ||
| L2F | 337 | 3.68 | 0.14 | 327 | 3.80 | 0.18 | 332 | 3.73 | 0.23 | 327 | 3.79 |
| PdL2F | 366 | 3.38 | 0.08 | 352 | 3.52 | 0.08 | 356 | 3.48 | 0.13 | 410 | 3.02 |
| L2F | 339 | 3.66 | 0.13 | 331 | 3.75 | 0.18 | 336 | 3.69 | 0.22 | 327 | 3.79 |
| PdL2F | 362 | 3.43 | 0.08 | 407 | 3.05 | 0.06 | 411 | 3.02 | 0.12 | 410 | 3.02 |
| L2F | 301 | 4.12 | 0.20 | 293 | 4.23 | 0.22 | 299 | 4.15 | 0.27 | 327 | 3.79 |
| PdL2F | 365 | 3.40 | 0.16 | 346 | 3.59 | 0.21 | 353 | 3.51 | 0.33 | 410 | 3.02 |
| L2F | 325 | 3.81 | 0.17 | 318 | 3.90 | 0.19 | 324 | 3.83 | 0.24 | 327 | 3.79 |
| PdL2F | 347 | 3.57 | 0.08 | 387 | 3.20 | 0.09 | 392 | 3.16 | 0.17 | 410 | 3.02 |
Fig 3UV-vis spectra of L2F and PdL2Fs.
Calculated, scaled and experimental vibrational modes of L2F and its complexes PdL2F.
| L2F | PdL2F | |||||
|---|---|---|---|---|---|---|
| Cal | Scal | Exp | Cal | Scal | Exp | |
| B3LYP | 2349 | 2274 | 2393 | - | - | - |
| B3P86 | 2092 | 2025 | 2393 | - | - | - |
| CAM-B3LYP | 2506 | 2426 | 2393 | - | - | - |
| PBE0 | 2214 | 2143 | 2393 | - | - | - |
| B3LYP | 3250 | 3146 | 3274 | 3245 | 3141 | 3225 |
| B3P86 | 3269 | 3164 | 3274 | 3265 | 3160 | 3225 |
| CAM-B3LYP | 3277 | 3172 | 3274 | 3276 | 3171 | 3225 |
| PBE0 | 3280 | 3175 | 3274 | 3276 | 3171 | 3225 |
| B3LYP | 1661 | 1608 | 1637 | 1643 | 1590 | 1616 |
| B3P86 | 1667 | 1613 | 1637 | 1662 | 1609 | 1616 |
| CAM-B3LYP | 1712 | 1657 | 1637 | 1695 | 1641 | 1616 |
| PBE0 | 1688 | 1634 | 1637 | 1677 | 1623 | 1616 |
| B3LYP | 3108 | 3008 | 3071 | 3139 | 3038 | 3041 |
| B3P86 | 3133 | 3032 | 3071 | 3155 | 3054 | 3041 |
| CAM-B3LYP | 3138 | 3037 | 3071 | 3170 | 3068 | 3041 |
| PBE0 | 3141 | 3040 | 3071 | 3251 | 3147 | 3041 |
| B3LYP | 3057 | 2959 | 2956 | 3037 | 2940 | 2960 |
| B3P86 | 3044 | 2946 | 2956 | 3051 | 2953 | 2960 |
| CAM-B3LYP | 3049 | 2951 | 2956 | 3061 | 2963 | 2960 |
| PBE0 | 3059 | 2961 | 2956 | 3061 | 2963 | 2960 |
Cal = Calculated; Scal = Scaled; Exp = Experimental
Fig 4FTIR spectra of L2F and PdL2F.
Hydrogen bonds in the ligand L2F and PdL2F complex.
| D --H ..A | D --H (Å) | H ..A (Å) | D --A (Å) | D --H ..A (°) |
|---|---|---|---|---|
| 0.83(2) | 1.86(3) | 2.619(2) | 152(3) | |
| 0.82(3) | 1.84(4) | 2.599(3) | 153(3) | |
| 0.93 | 2.46 | 3.376(8) | 169 | |
(symmetry codes; i = x,1/2-y,1/2+z)
Predicted and experimental 1H and 13C chemical shifts of L2F and its complex PdL2F.
| L2F | PdL2F | |||||
|---|---|---|---|---|---|---|
| 1H-NMR | Gas | PCM | Exp. | Gas | PCM | Exp. |
| OH | 12.8 | 13.5 | 13.25 | - | ||
| HC = N | 7.9 | 8.0 | 8.30 | 7.9 | 7.9 | 7.96 |
| Ar-H | 6.8 | 6.9 | 6.91–7.35 | 7.0 | 7.0 | 6.76–7.20 |
| CH3 | 1.5 | 1.3 | 0.97 | 1.2 | 1.1 | 1.02 |
| CH2 | 3.1 | 3.3 | 3.5 | 3.3 | 3.4 | 3.53 |
| C (OH) | 160 | 167 | 157.74 | - | ND | |
| HC = N | 164 | 172 | 164.74 | 164 | 163 | 164.4 |
| Ar-C | 113 | 121 | 116.35–119.51 | 115 | 116 | 117.76–120.66 |
| Ar-F | 157 | 164 | 156.34 | - | ND | |
| CH3 | 21 | 29 | 24.36 | 18 | 18 | 23.66 |
| -CH2- | 70 | 77 | 68.2 | 76 | 76 | 71.02 |
| -C(CH3)2 | 40 | 48 | 36.3 | 37 | 38 | 33.95 |
Fig 5Correlation curves between the experimental and predicted 13C NMR (right) and 1H NMR (left) chemical shifts of L2F Schiff base (up) and its complex PdL2F (bottom).
Crystallographic data and refinement parameters for L2F and PdL2F.
| Compound | L2F | PdL2F |
|---|---|---|
| C19H20F2N2O2 | C19H18F2N2O2Pd | |
| 346.37 | 450.75 | |
| 0(2) | 273(2) | |
| 0.71073 | 0.71073 | |
| Triclinic | monoclinic | |
| Pī | P21/c | |
| a = 6.1334(5), b = 9.2490(7), c = 16.3270(13) | a = 11.111(2), b = 13.701(3), c = 12.196(2) | |
| α = 102.110(2), β = 96.032(2), γ = 103.520(2) | β = 105.069(6) | |
| 868.84(12) | 1792.8(6) | |
| 2 | 4 | |
| 0.101 | 1.313 | |
| 364 | 904 | |
| 0.50 × 0.29 × 0.19 mm | 0.27 × 0.20 × 0.08 mm | |
| 25298 | 51046 | |
| 4327 | 4443 | |
| 2.930–28.370 | 2.973–28.353 | |
| -7< = h< = 8 | -14< = h< = 14 | |
| -12< = k< = 12 | -18< = k< = 18 | |
| -21< = l< = 21 | -16< = l< = 16 | |
| 1.052 | 1.106 | |
| 1855625 | 1890435 |
Fig 6Molecular structure of ligand drawn at 50% probability ellipsoids.
Some important bond lengths (Å) and angles (°) of L2F and PdL2F.
| Bond length/angle | L2F | PdL2F |
|---|---|---|
| 1.348(2) | 1.306(7) | |
| 1.349(3) | 1.308(7) | |
| 1.270(2) | 1.280(8) | |
| 1.458(2) | 1.480(7) | |
| 1.270(3) | 1.297(8) | |
| 1.456(3) | 1.467(7) | |
| - | 1.994(4) | |
| - | 1.997(5) | |
| - | 2.000(4) | |
| - | 2.013(4) | |
| - | 172.85(18) | |
| - | 80.42(17) | |
| - | 92.49(18) | |
| - | 92.33(18) | |
| - | 94.79(19) | |
| - | 172.33(18) | |
| - | -73.8(7) | |
| - | 170.5(5) | |
| - | 50.4(7) |
Fig 7Molecular structure of PdL2F complex drawn at 50% probability ellipsoids.
Fig 8Molecular packing of PdL2F complex viewed down a axis.
The non-hydrogenbonded hydrogen atoms are omitted for clarity.
The anticancer activity of L2F and its PdL2F complex against HCT116.
| Compound | IC50, μg/mL |
|---|---|
| 90.00 (less active) | |
| 4.1 (active) | |
| 1.70 | |
| 1.09 |